Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics

Area of Science:

• Oncology
• Proteomics
• Mass Spectrometry

Background:

• Predictive biomarkers are crucial for developing effective anticancer therapies.
• Identifying early indicators of therapeutic response can optimize treatment strategies.

Purpose of the Study:

• To investigate early proteomic changes as predictive biomarkers for anticancer therapy response using MALDI-MS.
• To assess the correlation between proteomic changes and therapeutic outcomes in HER2-transgenic mouse models.

Main Methods:

• Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was employed to analyze protein profiles in tumor sections.
• Mouse mammary tumor virus/HER2 transgenic mice were treated with erbB receptor inhibitors (OSI-774 and Herceptin).
• Changes in thymosin beta4 and ubiquitin levels were quantified and correlated with treatment effects.

Main Results:

• A significant reduction (>80%) in thymosin beta4 and ubiquitin levels predicted tumor cell proliferation inhibition, apoptosis, and tumor reduction.
• These proteomic changes were detectable within 16 hours of a single drug dose, preceding visible cellular activity.
• The observed proteomic changes were time- and dose-dependent and spatially correlated with the small-molecule inhibitor OSI-774.
• Early proteomic alterations successfully predicted therapeutic synergy and drug resistance to OSI-774 and Herceptin.

Conclusions:

• Early proteomic changes, measurable by MALDI-MS, serve as reliable predictors of therapeutic response to anticancer agents.
• This approach enables the prediction of treatment efficacy, synergy, and resistance, potentially guiding personalized cancer therapy.
• MALDI-MS-based proteomic analysis offers a valuable tool for evaluating both established and novel anticancer therapies.